MetabolicResearch Only

Mazdutide

IBI362

Compare Mazdutide prices

Lowest $/mg across vendors

Calculate dosing

Reconstitution

Overview

Mazdutide is a dual GLP-1 / glucagon receptor agonist licensed from Eli Lilly to Innovent Biologics for Greater China. Approved by China's NMPA in June 2025 for chronic weight management and in September 2025 for glycemic control in type 2 diabetes; NOT FDA-approved in the US.

Mechanism of Action

Co-agonism of GLP-1R and GCGR produces additive metabolic effects — GLP-1 suppresses appetite and slows gastric emptying while glucagon agonism increases energy expenditure and mobilizes hepatic fat.

Research Summary

Phase 3 GLORY-1 (Ji et al., NEJM 2025) in 610 Chinese adults with obesity/overweight reported mean weight loss of ~11.0% (4 mg) and ~14.0% (6 mg) vs +0.3% placebo at 48 weeks. Additional Phase 3 programs (GLORY-2 obesity, DREAMS-1/2/3 T2DM) supported the NMPA approvals; a 9 mg supplementary application for moderate-to-severe obesity is under NMPA review.

Dosing Information

Typical Dose

4–6 mg (9 mg under review)

Frequency

Weekly

Route

SubQ

Notes

Titrated over several weeks. Approved in China only; research-only in the US.

Verified testing for Mazdutide

Aggregated from 5 lab-verified Certificates of Analysis uploaded directly by labs. Purity averages exclude values outside [50%, 100%] to filter unit-misreads.

COAs

Verified labs

Avg purity

99.76%

±0.29%

Endotoxin tested

See every Mazdutide COA

Reported Side Effects

Nausea
Vomiting
Diarrhea
Decreased appetite

Contraindications

Personal or family history of medullary thyroid carcinoma
Multiple endocrine neoplasia syndrome type 2
Pregnancy

Research References

This platform provides informational tools only, not medical advice. This information is for educational purposes only. Consult a licensed provider.